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Background: Ongoing HIV-1 replication in lymphoid cells is one explanation of the persistence of HIV-1 reservoirs
despite highly active antiretroviral therapy (cART). We tested the potential of cART intensification by Maraviroc plus
Raltegravir to decrease proviral HIV-1 DNA levels in lymphoid cells during a randomized trial.
Patients and methods: We randomly assigned for 48 weeks 22 patients to continue their current first line regimen
of Truvada® plus Kaletra® or intensify it with Maraviroc and Raltegravir. The primary objective was to obtain a 50%
decrease in proviral HIV-1 DNA levels in lymphoid cells with intensification. Blood samples were drawn at W-2, W0,
W2, W4, W12, W24 and W48. Plasma viremia, cellular proviral DNA and cellular RNA, 2-LTR circles and lymphocytes
subsets were assayed using validated methods. Patients in the intensified group underwent a gut biopsy at baseline
and W48 to measure proviral DNA levels. Statistical analysis used parametric and non-parametric tests.
Results: Ten patients in each arm completed the trial. The 2 populations were comparable at baseline. No change
in the reservoir size was observed in the intensified arm compared to the control arm measured in peripheral blood
mononuclear cells (PBMCs). No change in the reservoir size was observed in gut proviral DNA in the intensified arm. In
this group, no increase in 2-LTR circles was observed as early as 2 weeks after intensification and no change was found
in residual plasma RNA levels measured by the single copy assay. However, a decrease in CD8+ T cells activation was
observed at 24 and 48 weeks, as well as in PBMCs HIV-1 RNA levels.
Conclusion: We conclude that the intensification of a Protease Inhibitor regimen with Maraviroc and Raltegravir does
not impact the blood proviral DNA reservoir of HIV but can decrease the cell-associated HIV RNA, the CD8 activation
and has a possible impact on rectal proviral HIV DNA in some patients.
Trial registration: ClinicalTrials.gov identifier number NCT00935480
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With the advent of combined antiretroviral therapy
(cART), HIV-1 replication can become undetectable in
the plasma for years. However, HIV-1 persists in lymphoid
reservoirs where residual low levels of viral replication can
be found [1]. Consequently, cART intensification could re-
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cART intensification in first line treated patients to
decrease the proviral HIV-1 reservoir in circulating
peripheral blood mononuclear cells (PBMCs). We used
Maraviroc, a CCR5 inhibitor and Raltegravir, an integrase
inhibitor for intensification, with the objective to get at
least a 50% decrease in proviral DNA levels in PBMCs.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Lafeuillade et al. AIDS Research and Therapy 2014, 11:33 Page 2 of 6
http://www.aidsrestherapy.com/content/11/1/33Patients and methods
Twenty-two adult patients on first line therapy with
Truvada® (1 pill/day) and Kaletra® 400/100 (2 pills twice
daily) were randomly assigned to continued cART of
add Maraviroc (150 mg twice a day) and Raltegravir
(400 mg twice a day) to their regimen.
Inclusion criteria included to be on first line therapy
with this regimen, having no contraindication to receive
Maraviroc and Raltegravir, have a plasma viral load <20
copies/ml for at least 12 weeks, no contraindication for
gut biopsies.
CD4+, CD8+ and CD8+CD38+ T cell subsets were mea-
sured by flow cytometry (BD Le Pont de Claix, France)
using commercially available monoclonal antibodies (BD
Le Pont de Claix, France).
HIV-1 RNA levels were measured in plasma by using
the Amplicor Monitor® assay (Roche Diagnostic, Meylan,
France). Patients with levels <20 copies/ml where tested
with the single copy assay (SCA) as previously reported
[2]. HIV-1 RNA titers were also measured in lymphoid
cells with a previously described technique evaluating
both un-spliced and multiply spliced RNA [3].
HIV-1 DNA levels were measured by using the Generic
HIV® assay (Biocentric, Bandol, France) according to
manufacturer’s instructions.Figure 1 Patients’ disposition during the trial.2-LTR quantification used a previously reported
technique [4].
Drug levels were measured by LC-MS.
CCR5 tropism was determined on PBMC HIV DNA
by sequencing according to the ANRS protocol [5] using
the geno2pheno with a cutoff of 20 percent.
Lymphoid tissue was obtained by sigmoid colon biop-
sies at 30 cm from the anus and processed as previously
reported [6].
Only patients included in the intensified arm of the
study were proposed to get gut biopsies at baseline and
W48.
Patients were analyzed in blood at W-2, W0, W2, W4,
W12, W24 and W48.
The randomization between the 2 groups was done by
using a computer-based method. It was performed by
our 2 technicians for clinical trials who also stored the
trial data locked in their office.
The primary objective was to detect at least a 50% de-
crease in PBMCs proviral DNA levels in the intensified
group and a calculation of at least 8 patients needed in
each arm was done.
The secondary objectives were to measure the evolution
of lymphocytes subsets, plasma viral load and PBMCs
HIV-1 RNA levels in the 2 groups.
Table 1 Baseline characteristics of patients
Arm 1 n = 10 Arm 2 n = 10
Age (Mean ± SD) years 54 ± 11 50 ± 12
Sex (M/F) 8/2 9/1
Duration of HIV infection
(Mean ± SD) in months
20 ± 17 15 ± 3
Duration of 1st line therapy
(Mean ± SD) in months
14 ± 12 10 ± 3
Duration of undetectable viral
load (Mean ± SD) in monhs
13 ± 19 6 ± 2
CD4+ cells/mm3 (Mean ± SD) 598 ± 380 744 ± 377
CD4+ cells/mm3 nadir
(Mean ± SD)
270 ± 120 290 ± 210
CD8+ cells/mm3 (Mean ± SD) 813 ± 414 927 ± 352
Viral load single copy assay
Nb positive cases
1/10 (6 copies/ml) 1/10 (8 copies/ml)
HIV DNA copies/106 PBMC
(Mean ± SD)
41 ± 37 24 ± 22
HIV RNA copies/106 PBMC
(Mean ± SD)
43 ± 28 32 ± 23
CCR5 tropism Nb of patients 10/10 9/10
For each parameter, the data are pooled results obtained at W-2 and at W0 is
used. SD: standard deviation.
a
b
Figure 2 Evolution in the 2 arms of immune markers over 48 weeks. 2a
Arm 2: controls. Results are shown as means with 95% confidence intervals
p = 0.002 compared to baseline.
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(IBM, Bois-Colombes, France) and used descriptive
statistics as well as parametric and non-parametric tests.
The Ethics Committee and the French Agency for
Drugs Security (ANSM) approved the protocol. All pa-
tients gave their written informed consent before inclu-
sion and the randomization was performed between
W-2 and W0.
The protocol number on ClinicalTrials.gov is
NCT00935480.Results
We screened a total of 30 patients and 10 were included
in each arm (Figure 1).
All included patients were naïve of Maraviroc and
Raltegravir and showed plasma HIV-1 RNA <20 copies/ml
for a median duration of 24 weeks (range: 12–36). Baseline
patients’ characteristics are shown in Table 1.
Eleven patients were randomized to the continuing
arm and 11 to the intensified arm.
In the continuing arm, 1 patient declined to follow the
protocol beyond screening and baseline as he hoped to
be in the intensified arm. In the intensified arm, 1 pa-
tient stopped antiretroviral therapy after week o and was
excluded from the study.c
: CD4+ T cells. 2b: CD8+ T cells. 3c: CD8+CD38+ T cells. Arm 1: intensified.
(bars). * paired t-test: p = 0.01 compared to baseline. ♯ unpaired t-test:
ba
Figure 3 Evolution in the 2 arms of PBMCs viral markers over
48 weeks in the 2 arms. 3a: proviral HIV-1 DNA in PBMC. 3b: HIV-1
ARN in PBMCs. Arm 1: intensified. Arm 2: controls. Results are shown
as means with 95% confidence intervals (bars). *non-parametric
paired test: p = 0.07 compared to baseline; **p = 0.06 compared
to baseline.
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Both groups were comparable in terms of age, sex,
duration of infection, CD4 cell count, HIV viremia,
(SCA) HIV DNA levels, CCR5 tropism and markers of
activation at baseline (Table 1).
Over the 48 weeks of follow-up, antiretrovirals were
well tolerated in both groups and no adverse event was
observed.Figure 4 Evolution of HIV-1 DNA in lymphoid cells taken from sigmoiAdherence was correct in each group, assessed by
residual through levels of lopinavir (group 1), lopinavir,
Maraviroc and raltegravir (group 2). In each case, levels
were in the needed range (data not shown).
Regarding the SCA, one patient in each group had
detectable viremia at levels <10 copies/ml. These 2 cases
did not show detectable viremia at any time point during
the trial. On the contrary one patient negative at base-
line in the control arm was found at 8 copies/ml at week
12 and 2 patients in the intensified arm were at 3 and 15
copies/ml respectively at weeks 12 and 24. These pa-
tients did not show any resistance selection at the time
cART was initiated (data not shown).
Regarding 2-LTR, no patient was positive at baseline.
No positive detection was found during the trial for all
cases but one in the intensified group who was mea-
sured at 5.84 2-LTR units/106 PBMC at week 2.
The mean CD4+ T cell counts did not change over
time in the 2 arms (Figure 2a).
The mean CD8+ T cell counts showed a statistically
significant decrease in the intensified arm compared to
baseline at weeks 24 and 48 (Figure 2b).
Regarding the CD8+CD38+ T cell counts, a statistically
significant decrease in the intensified arm compared to
baseline at weeks 24 and 48 was also found (Figure 2c).
Proviral DNA levels in PBMCs did not change over
time in the 2 arms (Figure 3a).
Mean HIV-1 RNA levels in PBMCs were similar in
both groups at baseline (Table 1). A decrease was ob-
served in the intensified arm at weeks 24 and 48 but not
in the control arm. These results reached statistical
significance (Figure 3b).
Regarding proviral DNA levels in gut cells, no trend
was observed (Figure 4) despite the fact that we mea-
sured DNA levels in cells as a whole and not in sorted
CD4+ T cells only [6,7].
HIV-1 RNA levels in gut cells could not be assessed
due to the lack of sufficient material left after measuring
HIV-1 DNA.d colon in the intensified group (copies/106 cells).
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Despite a nearly complete suppression of HIV-1 replica-
tion with cART, HIV-1 persists in lymphoid reservoirs
[8] and plasma viremia always rebounds when therapy is
stopped. These reservoirs are stable on cART even after
years of compliance. Two mechanisms, which are not
exclusive, have been proposed to explain this persist-
ence: ongoing viral replication and/or homeostatic
proliferation [9,10].
By adding 2 new antiretroviral drugs with different
mechanisms of action in first line Protease Inhibitor
treated patients, we tried to impact the stability of the
reservoir. The originality of this approach was the choice
of drugs and the long period of intensification. However,
no difference was found between intensified cases and
the control group up to 48 weeks regarding the primary
end point of the trial, which was a more than 50%
decrease in proviral DNA levels in circulating lymphoid
cells. Nevertheless we observed diverse patterns of pro-
viral DNA evolution in gut cells but due to the small
sample size we were unable to correlate these evolutions
to any characteristic of the patient. No increase in 2-LTR
levels, a marker of ongoing HIV-1 replication was demon-
strated as early as 2 weeks after intensification. No change
in CD4+ T cells was found but a late decrease of activation
markers (CD8+CD38+) was observed in the intensified
arm following a decrease of total CD8+ T cells. This de-
crease in activation markers might be due to the effect
of intensification on ongoing viral replication. Interest-
ingly, we also observed a decrease of PBMCs HIV-1
RNA levels in the intensified arm after 24 weeks that
can also reflect the reduction of ongoing viral replica-
tion, as this marker has been demonstrated to reflect
this replication [11].
Other trials have addressed the issue of cART intensi-
fication and showed conflicting results. In the study of
Buzon et al., an increase in 2-LTR was demonstrated by
adding Raltegravir [12]. In the trial reported by Dinoso
et al., no effect of intensification was obtained on the
residual viremia measured by the single copy assay [13].
To our knowledge, only two studies used Maraviroc
and Raltegravir in combination [14,15] and found nega-
tive results on the HIV reservoir.
Maraviroc has been shown to be an antiretroviral
drug, but also to increase the expression of latent HIV
[16]. It is impossible in our study to know if this effect
was induced as Maraviroc was combined with
Raltegravir.
Our study has some limitations. Firstly, as patients
were effectively treated, CCR5 tropism could only be
tested on archived virus. Secondly, the sample size was
small due to the fact that having to perform gut biopsies
discouraged patients. Thirdly, we were able only to
measure the HIV-1 reservoir by PCR techniques and notby culture of replication competent virus [17]. However
we observed a significant impact of intensification on
blood cells ongoing HIV replication and markers of lym-
phocytes activation. Regarding the results on rectal pro-
viral DNA, we cannot conclude due to the small sample
size and no control group for this test. Nevertheless,
previous studies have shown that rectal biopsies might
not be the best representative of gut HIV reservoirs,
compared to other locations like the ileum [18]. One
other possible confounding factor is the fact that we in-
cluded HIV naïve patients with a short time of undetect-
able viremia on cART. This could have explained the
persistence of ongoing viral replication.
Further studies are needed with larger samples to
confirm that ongoing viral replication is present in some
patients despite effective therapy and can be reduced by
drug intensification. This is a major question to resolve
before moving to therapeutic trials aimed at inducing a
HIV functional cure [19,20].
Conclusion
In the population studied, 48 weeks cART intensification
with Maraviroc and Raltegravir failed to decrease the
proviral HIV reservoir in circulating lymphocytes but
was able to decrease both lymphocytes activation and
ongoing viral replication. A possible effect on proviral
DNA in rectal cells was observed in some patients but
difficult to interpret due to the low sample size.
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